drugset
Drugs / ABT-493/ABT-530
last change Mar 2019 re-read 3 minutes ago

ABT-493/ABT-530

also known as G/P
Developed for
chronic hepatitis C virus infection
Investigated by
AbbVie

Trials 1

today NCT02707952 · Ph 3
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02707952 Feb → Nov 2016 chronic hepatitis C virus infection AbbVie Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ABT-493/ABT-530 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02707952 ↗
Known as G/P “Here, we report an integrated analysis of efficacy and safety of 8-week treatment with the all-oral, fixed-dose combination of the direct acting antivirals (DAA), glecaprevir...” PMID 30868245 ↗ Mar 2019
Action Inhibit “Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively.” PMID 29180522 ↗ Jan 2018
Route Oral “Here, we report an integrated analysis of efficacy and safety of 8-week treatment with the all-oral, fixed-dose combination of the direct acting antivirals (DAA), glecaprevir...” PMID 30868245 ↗ Mar 2019